増殖糖尿病網膜症の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

増殖糖尿病網膜症市場の世界需要は、2023年の63億3,000万米ドルから2032年には156億9,000万米ドル近くの市場規模に達し、調査期間2024～2032年のCAGRは10.62%に達すると推定されます。

増殖糖尿病網膜症（PDR）は、糖尿病網膜症の進行した重篤な病態であり、糖尿病患者に発症する可能性のある眼疾患です。糖尿病網膜症は糖尿病に関連した合併症で、眼の奥にある光に敏感な組織である網膜血管に影響を及ぼします。PDRは、網膜における異常な血管の増殖（新生血管）を特徴とします。

市場力学

増殖糖尿病網膜症（PDR）市場はいくつかの要因によって牽引されているが、主に糖尿病、特に2型糖尿病の世界の有病率の増加が影響しています。高齢化の進展は糖尿病が長期化するリスクをさらに高め、増殖糖尿病網膜症の発症率の上昇につながります。医療専門家や患者の意識の高まりと網膜画像診断の技術的進歩が相まって、早期発見と的を絞った治療が容易になっています。薬理学的介入を含む治療アプローチにおける継続的な技術革新は、PDR管理の進化に寄与しています。医療サービスへのアクセスの改善、政府の取り組み、医療機関や研究機関の協力により、PDRに対する全体的な対応がさらに強化されています。早期介入に不可欠な定期的な眼科検診と糖尿病管理を推進する上で、患者教育とエンパワーメントが極めて重要な役割を果たしています。糖尿病網膜症が重大な健康問題であるという世界の認識は、経済発展や医療インフラの改善と相まって、増殖糖尿病網膜症に関連する課題に対処する包括的な戦略を形成し、視力障害の軽減と患者の転帰の向上を目指しています。

この調査レポートは、ポーターのファイブフォースモデル、市場魅力度分析、バリューチェーン分析を対象としています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、増殖糖尿病網膜症の世界市場における各セグメントを包括的に評価することもできます。増殖糖尿病網膜症産業の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

増殖糖尿病網膜症市場レポートでは、国・地域レベルのセグメントに関する詳細なデータを提供することで、戦略担当者が各製品・サービスの対象層を特定し、今後のビジネスチャンスに役立てることができます。

薬剤クラス別

• 抗VEGF薬
• 副腎皮質ステロイド

投与形態別

• 注射剤
• 経口剤
• その他

流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

地域分析

このセクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける増殖糖尿病網膜症市場の現在と将来の需要を強調する地域展望をカバーします。さらに、本レポートでは、著名な全地域にわたる個々の用途セグメントの需要・推定・予測に焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

• 市場のハイライト
• 世界市場スナップショット

第3章 増殖糖尿病網膜症-産業分析

• イントロダクション-市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• 業界動向
• ポーターのファイブフォース分析
• 市場魅力度分析

第4章 バリューチェーン分析

• バリューチェーン分析
• 原材料分析
  • 原材料リスト
  • 原材料メーカーリスト
  • 主要原材料の価格動向
• 潜在的バイヤーのリスト
• マーケティングチャネル
  • 直接マーケティング
  • 間接マーケティング
  • マーケティングチャネル発展動向

第5章 増殖糖尿病網膜症の世界市場分析：薬剤クラス別

• 薬剤クラス別概要
• 実績データと予測データ
• 薬剤クラス別分析
• 抗VEGF薬
• 副腎皮質ステロイド

第6章 増殖糖尿病網膜症の世界市場分析：投与形態別

• 投与形態別概要
• 実績データと予測データ
• 投与形態別分析
• 注射剤
• 経口剤
• その他

第7章 増殖糖尿病網膜症の世界市場分析：流通チャネル別

• 流通チャネル別概要
• 実績データと予測データ
• 流通チャネル別分析
• 病院薬局
• 小売薬局
• オンライン薬局

第8章 増殖糖尿病網膜症の世界市場分析：地域別

• 地域別展望
• イントロダクション
• 北米売上分析
  • 概要、実績と予測
  • 北米：セグメント別
  • 北米：国別
  • 米国
  • カナダ
  • メキシコ
• 欧州売上分析
  • 概要、実績と予測
  • 欧州：セグメント別
  • 欧州：国別
  • 英国
  • フランス
  • ドイツ
  • イタリア
  • ロシア
  • その他の欧州
• アジア太平洋売上分析
  • 概要、実績と予測
  • アジア太平洋：セグメント別
  • アジア太平洋：国別
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア
  • 東南アジア
  • その他のアジア太平洋
• ラテンアメリカ売上分析
  • 概要、実績と予測
  • ラテンアメリカ：セグメント別
  • ラテンアメリカ：国別
  • ブラジル
  • アルゼンチン
  • ペルー
  • チリ
  • その他のラテンアメリカ
• 中東・アフリカ売上分析
  • 概要、実績と予測
  • 中東・アフリカ：セグメント別
  • 中東・アフリカ：国別
  • サウジアラビア
  • アラブ首長国連邦
  • イスラエル
  • 南アフリカ
  • その他の中東・アフリカ

第9章 増殖糖尿病網膜症企業の競合情勢

• 増殖糖尿病網膜症市場競争
• 提携・協力・契約
• 合併・買収
• 新製品の上市
• その他の開発

第10章 企業プロファイル

• 企業シェア分析
• 市場集中度
• Genentech Inc.
• Novartis AG
• Regeneron Pharmaceuticals Inc.
• Pfizer Inc.
• Merck KGaA
• Cipla Inc.
• AbbVie Inc.
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co. Ltd.
• Alimera Sciences
• Intas Pharmaceuticals Ltd.

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Anti-VEGF Agents Market Sales by Geography (USD MN)
• Corticosteroids Market Sales by Geography (USD MN)
• Analysis Market by Mode of Administration (USD MN)
• Injectable Market Sales by Geography (USD MN)
• Oral Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Proliferative Diabetic Retinopathy Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Proliferative Diabetic Retinopathy Report
• Market Research Process
• Market Research Methodology
• Global Proliferative Diabetic Retinopathy Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Mode of Administration
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Anti-VEGF Agents Market Sales by Geography (USD MN)
• Corticosteroids Market Sales by Geography (USD MN)
• Global Market Analysis by Mode of Administration (USD MN)
• Injectable Market Sales by Geography (USD MN)
• Oral Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Pharmacies Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

The global demand for Proliferative Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.69 Billion by 2032 from USD 6.33 Billion in 2023 with a CAGR of 10.62% under the study period 2024 - 2032.

Proliferative diabetic retinopathy (PDR) is an advanced and serious stage of diabetic retinopathy, an eye condition that can occur in individuals with diabetes. Diabetic retinopathy is a diabetes-related complication that affects the retinal blood vessels, the light-sensitive tissue at the back of the eye. PDR is characterized by the growth of abnormal blood vessels (neovascularization) in the retina.

MARKET DYNAMICS

The Proliferative diabetic retinopathy (PDR) market is driven by several factors, primarily influenced by the increasing global prevalence of diabetes, particularly type 2 diabetes. A growing aging population further raises the risk of prolonged diabetes, leading to a higher incidence of diabetic retinopathy progressing to the proliferative stage. Increased awareness among healthcare professionals and patients, coupled with technological advancements in retinal imaging, facilitates early detection and targeted treatment. Ongoing innovations in treatment approaches, including pharmacological interventions, contribute to the evolving landscape of PDR management. Improved access to healthcare services, government initiatives, and collaborations among healthcare organizations and research institutions further enhance the overall response to PDR. Patient education and empowerment play pivotal roles in promoting regular eye screenings and diabetes management, which is crucial for early intervention. The global recognition of diabetic retinopathy as a significant health concern, coupled with economic development and healthcare infrastructure improvements, collectively shapes a comprehensive strategy to address the challenges associated with proliferative diabetic retinopathy, aiming to reduce vision impairment and enhance patient outcomes.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of proliferative diabetic retinopathy. The growth and trends of proliferative diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the proliferative diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Anti-VEGF Agents
• Corticosteroids

By Mode Of Administration

• Injectable
• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Proliferative Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Proliferative Diabetic Retinopathy market include Genentech, Inc., Novartis AG, Regeneron Pharmaceuticals, Inc., Pfizer Inc., Merck KGaA, Cipla Inc., AbbVie Inc., Bausch Health Companies Inc., Santen Pharmaceutical Co., Ltd., Alimera Sciences, Intas Pharmaceuticals Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PROLIFERATIVE DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Mode of Administration
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Anti-VEGF Agents Historic and Forecast Sales by Regions
• 5.5 Corticosteroids Historic and Forecast Sales by Regions

6 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY MODE OF ADMINISTRATION

• 6.1 Overview by Mode of Administration
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Mode of Administration
• 6.4 Injectable Historic and Forecast Sales by Regions
• 6.5 Oral Historic and Forecast Sales by Regions
• 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1 Overview by Distribution Channel
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Distribution Channel
• 7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 7.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL PROLIFERATIVE DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE PROLIFERATIVE DIABETIC RETINOPATHY COMPANIES

• 9.1. Proliferative Diabetic Retinopathy Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF PROLIFERATIVE DIABETIC RETINOPATHY INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Genentech Inc.
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Novartis AG
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Regeneron Pharmaceuticals Inc.
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Pfizer Inc.
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. Merck KGaA
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Cipla Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. AbbVie Inc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Bausch Health Companies Inc.
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. Santen Pharmaceutical Co. Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Alimera Sciences
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Intas Pharmaceuticals Ltd.
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies